Deputy CEO and Technical Director Tom McKillop, PhD, will become CEO of the Zeneca Group's drug unit effective July 1. He succeeds David Friend, CEO since 1987, who will retire. McKillop, 50, joined ICI Corporate Research Laboratory in 1969, and held a variety of technical positions within ICI leading to his appointment in 1989 as technical director of ICI Pharmaceuticals with international responsibility for R&D and production. In 1992, he became deputy CEO, and he retained the titles when Zeneca was demerged from ICI in June 1993
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth